Navigation Links
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus

olerated. Frequency and severity of adverse events were similar to placebo, with no increase at higher doses. Among the Phase 2 study findings was a significantly improved response rate among serologically active patients at Week 52, as defined by an improvement in SELENA SLEDAI score of 4 points or greater, no new BILAG A flare and no more than one new BILAG B flare, and no worsening in Physician's Global Assessment (46% for LymphoStat-B versus 29% for placebo, p<0.01). This combination of measures is the primary efficacy endpoint in the Phase 3 clinical trials.

The data presented at EULAR 2007 demonstrated that LymphoStat-B continued to reduce the signs and symptoms of SLE disease activity throughout the 24- week extension phase of the study, demonstrated durable clinical and biological activity at Week 76, and appeared safe and well tolerated, with no increase in frequency and or severity of adverse events. The evidence of continuing improvement from Week 52 to Week 76 includes:

    -- An increase from 46% to 56% among serologically active patients in the

       patient response rate selected as the primary efficacy endpoint of the

       Phase 3 trials.


    -- An increase from 29% to 38% in the reduction in SLE disease activity

       among serologically active patients, as measured by SELENA SLEDAI.


    -- An increase from 33% to 41% in the reduction in SLE disease activity

       among serologically active patients, as measured by the Physician's

       Global Assessment.


    -- An increase in the mean improvement in health-related quality of life

       from 3.0 points to 3.4 points among serologically active patients, as

       measured by the SF-36 Physical Component Summary score.


    -- A durable reduction in anti-dsDNA autoantibodies (at least 50% or

       negative) among patients who were positive for anti-dsDNA at baseline

       (30% at Week 52; 34% at Week 76).


    -- Durable or increased reductions from Week 52 t
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
Post Your Comments:
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/10/2014)... , July 11, 2014  Major advances in ... cancer are being highlighted in a three-day Oncology ... from 10-12 July, 2014.  Renowned national and international cancer ... best practices and exchange knowledge on modern technologies ... and efficient. The Summit will ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... Calif., Jan. 5, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... Officer of BioMarin, will present a company update at the ... Monday, January 10, 2011 at 2:30 p.m. PT.   ... the conference call via the investor section of the BioMarin ...
... 5, 2011 Ikaria, Inc. today announced that the ... (nitric oxide) for inhalation an additional six months of ... exclusivity for INOMAX from January 2013 to July 2013. ... clinical trials of INOMAX in pre-term infants at risk ...
Cached Medicine Technology:BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference 2FDA Extends Marketing Exclusivity for INOMAX® 2FDA Extends Marketing Exclusivity for INOMAX® 3
(Date:7/12/2014)... CA (PRWEB) July 12, 2014 For those ... are bodies can readily absorb the nutrients in food. The ... particles that are small enough to be absorbed by human ... team, a lack of enzymes in regular food is the ... a product that was started by Michelle DelPresto, a mother ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major Developed ... PCCs and Recombinant Products to Drive Market,” which ... in the US, UK, France, Germany, Italy, Spain, ... of market size for 2013, along with market ... that are being treated using the five major ...
(Date:7/12/2014)... As reported in this July 1st ... Technology), the June 25th, 2014 Supreme Court ruling in Riley ... It was also met with both cheers and jeers ... was seen from an individual privacy perspective, or a law ... is now precedent which will require law enforcement officials to ...
(Date:7/12/2014)... July 12, 2014 Dubai is buzzing ... legend is heading to the UAE. The National ... will be in the UAE from 28-31 October to ... support of diabetes awareness. The event is being organized ... and event management company based in Dubai. The announcement ...
(Date:7/12/2014)... Texas (PRWEB) July 12, 2014 ... Breastfeeding Made Simple as a valuable new resource for ... roughly two-thirds of American women work away from their ... sources touting the benefits of breastfeeding, but often feel ... to nurse their babies. With its evidence-based insights, and ...
Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2
... for the Cure,s Global Promise, DALLAS, Oct. ... the,leader of the global breast cancer movement, is ... Hewko as vice president of,international, reporting to Komen ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ), Hewko will guide ...
... Members who choose Regence,s,Health Savings Account (HSA) will ... company has added U.S. Bank as a banking partner. ... care banking,and its strong consumer track record., "We ... and,brand like U.S. Bank to offer our members the ...
... Barnett, London, Ontario, receives the Karolinska Stroke Award for ... SEK. The laureate will receive the prize from the ... Stroke Update meeting in Stockholm November 17, 2008. ... award. The Karolinska Institutet also awards the Nobel ...
... ANGELES, Oct. 29 George Abercrombie, president ... address Los Angeles,business leaders at the National ... He plans to tell them,that the threat ... challenges,unlike those anticipated with traditional emergency preparedness ...
... Cojocaru forms Team Cojo to fight PKD, ... own life-saving,kidney transplant, fashion critic and Entertainment Tonight ... the 12.5 million people,worldwide affected by Polycystic Kidney ... world,s most common, life-threatening genetic,diseases, affecting more people ...
... Health Literacy Month, recognized in October, promotes ... information. According to the National Assessment of Adult ... health literacy - skills needed to manage their ... the focus of an ongoing study at the ...
Cached Medicine News:Health News:Susan G. Komen for the Cure(R) Strengthens Global Mission With Addition of Vice President, International 2Health News:Susan G. Komen for the Cure(R) Strengthens Global Mission With Addition of Vice President, International 3Health News:Regence Teams With U.S. Bank to Offer New Health Savings Account Solution 2Health News:Dr. Henry Barnett becomes first person outside Europe to receive Karolinska Stroke Award 2Health News:CEO to Address Los Angeles Business Leaders About Developing Pandemic and Business Continuity Plans 2Health News:CEO to Address Los Angeles Business Leaders About Developing Pandemic and Business Continuity Plans 3Health News:Cojo to Hit the Streets of LA for 2008 Walk for PKD 2Health News:$8.6 million grant to MU will fund efforts to improve health literacy, health outcomes 2
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
Inquire...
Inquire...
Medicine Products: